AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: both buying and selling, $3K to $45K in total in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- $3K to $45K tradedMixed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 5 added, 4 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $38.04
- 52-wk high
- $61.11
- High
- $38.77
- 52-wk low
- $34.15
- Low
- $37.89
- Prev close
- $38.31
- Mkt cap
- $170.93B
- P/E
- 9.7x
- Volume
- 20.60M
- Fwd P/E
- 11.8x
- Beta
- 0.34
- Div yield
- 4.64%
- P/S
- 0.5x
- P/B
- 5.0x
- Profit margin
- +35.3%
- Op margin
- +42.5%
- ROE
- +59.8%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about NVO filings
Are insiders buying or selling Novo Nordisk A/S (NVO) stock?
Neither. Novo Nordisk A/S (NVO) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded NVO recently?
Rep. Kevin Hern (R) sold $1K to $15K on Sep 10, 2026, disclosed 15 days later. Rep. Kevin Hern (R) sold $1K to $15K on Aug 31, 2026, disclosed 25 days later. Rep. Scott Scott Franklin (R) bought $1K to $15K on Aug 26, 2026, disclosed 22 days later. In total, 2 members disclosed 3 NVO trades with trade dates in the last 180 days, filed a median 22 days after trading.
How current is this NVO smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (1)
- AL
Alger
$235.3M
bought
Sells/Trims (2)
- TS
Two Sigma
$230.3M
trimmed
- SU
Susquehanna
$177.3M
trimmed
What Congress is doing
Buys (1)
Sells (2)
How top traders are positioned
No tracked top-trader positions in NVO right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 17.1% above what analysts expected.
Earnings per share
$0.82 expected
Reports Nov 4, 2026, in 34 days
Estimates as of Sep 30, 2026
EPS expected
$4.68 to $5.33
Revenue expected
9 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
Is the business strong?
Fairly priced and profitable.
- Net margin
- 35.3%
- P/E
- 9.70
- Forward P/E
- 11.83
- Market cap
- $170.9B
Valuation
- P/S0.52
- P/B4.97
- Dividend yield4.6%
Quality
- Operating margin42.5%
- ROE59.8%
- ROA18.7%
Growth
- Beta0.34
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
NeutralSep 29Novo Nordisk Bets On Once-Weekly China Developed Obesity Pill In Deal Worth $2.6 Billion
BullishSep 29Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
BullishSep 29Novo’s next-gen weight-loss drug outperforms Zepbound in new trial
BullishSep 27Can Novo Nordisk (NVO) Find a Second Act Before its First One Fades?
NeutralSep 27Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
NeutralSep 26What's Going on With Novo Nordisk Stock on Friday?
NeutralSep 25This week in charts: Novo’s rise and fall and AI biotechs’ big haul
BearishSep 25
Macro
32 macro signals shaping NVO right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results